JO3568B1 - عوامل ربط cd123 واستخداماتها - Google Patents

عوامل ربط cd123 واستخداماتها

Info

Publication number
JO3568B1
JO3568B1 JOP/2015/0216A JOP20150216A JO3568B1 JO 3568 B1 JO3568 B1 JO 3568B1 JO P20150216 A JOP20150216 A JO P20150216A JO 3568 B1 JO3568 B1 JO 3568B1
Authority
JO
Jordan
Prior art keywords
span
dir
rtl
antibodies
ltr
Prior art date
Application number
JOP/2015/0216A
Other languages
English (en)
Inventor
Wheeler John
Gaudet Francois
Luo Jinquan
Li Yingzhe
H Tam Susan
M Attar Ricardo
Teplyakov Alexey
Wu Sheng-Jiun
F Nemeth Jennifer
Mcdaid Ronan
C Harman Benjamin
C Pomerantz Steven
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3568B1 publication Critical patent/JO3568B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

بولي نوكليوتيد تخليقي معزول يشفر الجسم المضاد ثنائي النوعية<span dir="LTR"> HC1</span>، <span dir="LTR">HC2</span>، يشتمل<span dir="LTR"> LC1 </span>أو<span dir="LTR"> HC2 </span>من<span dir="LTR"> CD123 (IL3-Rα) x CD3 </span>أو شظية رابطة ثنائية النوعية وفقًا لأي من عناصر الحماية 31 إلى 66<span dir="LTR">.</span> <span dir="RTL">تم بهذه الوثيقة توفير أجسام مضادة ترتبط على نحو محدد للمناعة بـ </span>CD123<span dir="RTL">. يتعلق الاختراع الحالي ببولي نوكليوتيدات يمكنها تشفير الأجسام المضادة التي تم توفيرها والتي لها نوعية تجاه </span>CD123<span dir="RTL"> أو الشظايا الرابطة لمولِّدت الضد، خلايا تعبر عن الأجسام المضادة التي تم توفيرها أو شظايا رابطة لمولِّدت ضد، وكذلك النواقل المرتبطة وأجسام مضادة مرقَّمة بصورة قابلة للكشف أو شظايا رابطة لمولِّدت ضد. إضافةً إلى ذلك، طرق لاستخدام الأجسام المضادة التي تم توفيرها تم وصفها. على سبيل المثال، يمكن استخدام الأجسام المضادة التي تم توفيرها لتشخيص، أو علاج، أو مراقبة تقدم سرطان يعبر وراثيًا عن </span>CD123<span dir="RTL">، أو تراجعه، أوثباته؛ لتحديد ما إذا كان ينبغي معالجة مريض من السرطان أم لا؛ أو لتحديد ما إذا كان الخاضع مصابًا بسرطان يعبر وراثيًا عن </span>CD123<span dir="RTL"> أم لا وبالتالي يستجيب للعلاج بعلاج مضاد للسرطان له نوعية تجاه </span>CD123<span dir="RTL">، مثل الأجسام متعددة النوعية المضادة لـ </span>CD123<span dir="RTL"> و</span>CD3<span dir="RTL"> والتي ورد وصفها هنا.</span>
JOP/2015/0216A 2014-09-05 2015-09-03 عوامل ربط cd123 واستخداماتها JO3568B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462046682P 2014-09-05 2014-09-05

Publications (1)

Publication Number Publication Date
JO3568B1 true JO3568B1 (ar) 2020-07-05

Family

ID=54150667

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0216A JO3568B1 (ar) 2014-09-05 2015-09-03 عوامل ربط cd123 واستخداماتها

Country Status (39)

Country Link
US (1) US9850310B2 (ar)
EP (2) EP3722315A1 (ar)
JP (2) JP6805130B2 (ar)
KR (1) KR102540192B1 (ar)
CN (1) CN107074956B (ar)
AR (1) AR101765A1 (ar)
AU (1) AU2015311931B2 (ar)
CA (1) CA2959171C (ar)
CL (1) CL2017000515A1 (ar)
CO (1) CO2017002196A2 (ar)
CR (1) CR20170079A (ar)
CY (1) CY1122858T1 (ar)
DK (1) DK3189081T3 (ar)
EA (1) EA037647B1 (ar)
EC (1) ECSP17020812A (ar)
ES (1) ES2791249T3 (ar)
HR (1) HRP20200745T1 (ar)
HU (1) HUE048791T2 (ar)
IL (1) IL250770B (ar)
JO (1) JO3568B1 (ar)
LT (1) LT3189081T (ar)
MA (2) MA40609B1 (ar)
ME (1) ME03724B (ar)
MX (1) MX384424B (ar)
MY (1) MY186337A (ar)
NI (1) NI201700025A (ar)
PE (1) PE20171556A1 (ar)
PH (1) PH12017500472A1 (ar)
PL (1) PL3189081T3 (ar)
PT (1) PT3189081T (ar)
RS (1) RS60305B1 (ar)
SG (1) SG11201701599UA (ar)
SI (1) SI3189081T1 (ar)
SM (1) SMT202000253T1 (ar)
TW (1) TWI693233B (ar)
UA (1) UA120060C2 (ar)
UY (1) UY36289A (ar)
WO (1) WO2016036937A1 (ar)
ZA (1) ZA201702369B (ar)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
US10100118B2 (en) 2015-04-08 2018-10-16 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
AU2016285552B2 (en) 2015-06-29 2022-10-13 Immunogen, Inc. Anti-CD123 antibodies and conjugates and derivatives thereof
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
WO2017201493A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3493844A4 (en) 2016-05-20 2021-03-24 Harpoon Therapeutics Inc. SINGLE DOMAIN SERUM ALBUMIN BINDING PROTEIN
AU2017276604B2 (en) 2016-06-06 2020-02-27 F. Hoffmann-La Roche Ag Fusion proteins for ophthalmology with increased eye retention
MX2018014950A (es) 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
TWI790206B (zh) * 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
CN109952112B (zh) 2016-09-21 2024-09-06 阿帕特夫研究和发展有限公司 Cd123结合蛋白和相关的组合物和方法
AU2017363300A1 (en) 2016-11-23 2019-06-20 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
WO2018098356A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
EP3548055A4 (en) 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
EP3576793A4 (en) * 2017-02-06 2021-03-31 Dana Farber Cancer Institute, Inc. COMPOSITIONS AND PROCEDURES FOR ENHANCING ANTIBODY-MEDIATED RECEPTOR SIGNALING
AU2018224094B2 (en) 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
EP3621994A4 (en) 2017-05-12 2020-12-30 Harpoon Therapeutics, Inc. MESOTHELIN BINDING PROTEINS
WO2019034580A1 (en) 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3
WO2019050521A1 (en) * 2017-09-07 2019-03-14 Macrogenics, Inc. DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
MX2020004381A (es) * 2017-10-27 2020-08-20 Pfizer Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
KR20200098590A (ko) 2017-12-12 2020-08-20 마크로제닉스, 인크. 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
JP7337079B2 (ja) 2018-02-15 2023-09-01 マクロジェニクス，インコーポレーテッド 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用
CN120399075A (zh) 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
UA130542C2 (uk) 2018-05-16 2026-03-18 Янссен Байотек, Інк. Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
PE20211916A1 (es) 2018-05-24 2021-09-28 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos
JOP20190116A1 (ar) * 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
MA52772A (fr) 2018-05-24 2021-04-14 Janssen Biotech Inc Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
KR102302393B1 (ko) * 2018-10-17 2021-09-16 주식회사 굳티셀 Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
MX2021010857A (es) * 2019-03-11 2021-12-15 Janssen Biotech Inc Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
US11591395B2 (en) 2019-04-19 2023-02-28 Janssen Biotech, Inc. Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
MA55903A (fr) * 2019-05-08 2022-03-16 Janssen Biotech Inc Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t
AU2020275002A1 (en) 2019-05-14 2021-12-23 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
CN113912697B (zh) * 2019-07-24 2023-05-30 暨南大学 靶向cd133的结合蛋白与应用
GB201912681D0 (en) 2019-09-04 2019-10-16 Eth Zuerich Bispecific binding agent that binds to cd117/c-kit and cd3
IL295434A (en) 2020-02-21 2022-10-01 Macrogenics Inc cd137 binding molecules and their uses
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
JP2023517660A (ja) 2020-03-13 2023-04-26 ヤンセン バイオテツク，インコーポレーテツド シグレック３／ｃｄ３３に結合させるための材料及び方法
BR112022023392A2 (pt) * 2020-05-19 2022-12-20 Janssen Biotech Inc Composições que compreendem um agente terapêutico de redirecionamento de células t e um inibidor da via de adesão de vla-4
JP7770339B2 (ja) 2020-05-19 2025-11-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫応答を誘導するためのコンジュゲートポリペプチドおよびワクチン
TW202227495A (zh) 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
KR20230112632A (ko) * 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
TWI905354B (zh) 2020-12-31 2025-11-21 法商英耐特醫藥公司 結合至NKp46及CD123之多功能自然殺手 (NK) 細胞接合體
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
KR20240008345A (ko) 2021-05-18 2024-01-18 얀센 바이오테크 인코포레이티드 T 세포 재유도 치료제 및 항-cd44 치료제를 포함하는 조성물
IL308609A (en) 2021-05-19 2024-01-01 Asher Biotherapeutics Inc IL-21 polypeptides and target constructs
CN118103070A (zh) * 2021-08-09 2024-05-28 默克专利有限公司 解偶联t细胞介导的肿瘤细胞毒性与促炎细胞因子释放的蛋白质
CN118574646A (zh) * 2022-01-19 2024-08-30 上海优替济生生物医药有限公司 环状rna及其用途
EP4507790A1 (en) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
KR20250017240A (ko) 2022-05-27 2025-02-04 사노피 FC-조작을 갖는 NKp46 및 BCMA 변이체에 결합하는 자연 살해(NK) 세포 관여자
CN120857940A (zh) 2023-02-17 2025-10-28 瑞泽恩制药公司 对cd3/taa双特异性抗体有反应的诱导型nk细胞

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6177078B1 (en) 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
PT1015576E (pt) 1997-09-16 2005-09-30 Egea Biosciences Llc Metodo para a sintese quimica completa e montagem de genes e de genomas
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
JP5694923B2 (ja) * 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
EP2480888B1 (en) * 2009-09-25 2016-11-30 XOMA Technology Ltd. Screening methods
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
PT2850106T (pt) * 2012-05-18 2022-07-18 Aptevo Res & Development Llc Imunofusão biespecífica (bif) de scfv de ligação a cd123 e cd3

Also Published As

Publication number Publication date
EP3189081A1 (en) 2017-07-12
ME03724B (me) 2021-01-20
US20160068605A1 (en) 2016-03-10
US9850310B2 (en) 2017-12-26
PE20171556A1 (es) 2017-10-27
JP6805130B2 (ja) 2020-12-23
MX2017002891A (es) 2017-10-11
EA201790530A1 (ru) 2018-03-30
CY1122858T1 (el) 2021-05-05
PT3189081T (pt) 2020-05-25
ES2791249T3 (es) 2020-11-03
KR102540192B1 (ko) 2023-06-02
MA40609B1 (fr) 2020-05-29
CO2017002196A2 (es) 2017-07-28
SI3189081T1 (sl) 2020-07-31
CA2959171C (en) 2023-11-14
SMT202000253T1 (it) 2020-07-08
CN107074956A (zh) 2017-08-18
NI201700025A (es) 2017-06-22
IL250770A0 (en) 2017-04-30
IL250770B (en) 2020-10-29
SG11201701599UA (en) 2017-03-30
JP2017529838A (ja) 2017-10-12
MY186337A (en) 2021-07-13
AU2015311931B2 (en) 2020-09-03
BR112017004322A2 (pt) 2017-12-05
JP2021050216A (ja) 2021-04-01
UY36289A (es) 2016-04-01
EP3189081B1 (en) 2020-02-19
MA53145A (fr) 2021-05-19
HRP20200745T1 (hr) 2020-08-07
WO2016036937A1 (en) 2016-03-10
LT3189081T (lt) 2020-05-11
EP3722315A1 (en) 2020-10-14
ECSP17020812A (es) 2018-07-31
CL2017000515A1 (es) 2018-03-16
KR20170049554A (ko) 2017-05-10
PH12017500472A1 (en) 2017-07-31
CA2959171A1 (en) 2016-03-10
HUE048791T2 (hu) 2020-09-28
CR20170079A (es) 2017-04-27
AU2015311931A1 (en) 2017-03-16
EA037647B1 (ru) 2021-04-27
TWI693233B (zh) 2020-05-11
MX384424B (es) 2025-03-14
AR101765A1 (es) 2017-01-11
PL3189081T3 (pl) 2020-10-05
UA120060C2 (uk) 2019-09-25
RS60305B1 (sr) 2020-07-31
ZA201702369B (en) 2018-12-19
DK3189081T3 (da) 2020-05-04
CN107074956B (zh) 2021-11-26
TW201625687A (zh) 2016-07-16

Similar Documents

Publication Publication Date Title
JO3568B1 (ar) عوامل ربط cd123 واستخداماتها
CL2019000146A1 (es) Anticuerpos anti - gprc5d, moléculas de unión de antigeno bioespecificos que enlazan gprc5d y cd3, y usos relacionados.
ZA201708265B (en) Tigit-binding agents and uses thereof
PE20200012A1 (es) Anticuerpos mono- y biespecificos que se unen al factor de coagulacion ix y al factor de coagulacion x
MX2017013298A (es) Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b.
EA201791093A1 (ru) Антитела к cd47, способы и применение
JO3792B1 (ar) تركيبات الجسم المضاد لـ flt3 و cd3
EA201791485A1 (ru) Анти-cd47-антитела и их применения
PH12017501190A1 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
PH12018500938A1 (en) Anti-il1rap antibodies, bispecific antigen binding molecules that bind ili1rap and cd3, and uses thereof
GEAP201914392A (en) Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
PH12017501166A1 (en) Antibodies to tight
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112018016697A2 (pt) anticorpo revestido, quimérico ou humanizado, composição farmacêutica, e, método de tratamento.
MX2016014210A (es) Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
PH12016501366A1 (en) Novel anti-baff antibodies
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения